SLC35A2 and cancer: Despite immunotherapy has shown promise in treating several cancers in past years, our study revealed that SLC35A2 is highly expressed in microsatellite stable (MSS) colorectal tumors, which is in consistent with unresponsiveness to the immunotherapy 47.